Table 2.

Conditioning regimens

Regimens	n (%)
FBM (Fludarabine, BCNU, Melphalan) Fludarabine 5 × 30 mg/m2 on five consecutive days (d-8 to d-4), BCNU 2 × 150 mg/m2 (d-6, d-5), Melphalan 110 mg/m2 on d-3 (age ≥ 55 years) or Melphalan 140 mg/m2 on d-3 (age < 55 years)	144 (54.1%)
FTM (Fludarabine, Thiopeta, Melphalan) Fludarabine 5 × 30 mg/m2 (d-7 to d-3), Thiopeta 5 mg/kg (d-6), Melphalan 110 mg/m2 on d-3 (age ≥ 55 years) or Melphalan 140 mg/m2 on d-3 (age < 55 years)	31 (11.6%)
FLAMSA-RIC Treosulfan, Fludarabine FLAMSA regimen (d-12 to d-9): Fludarabine 4 × 30 mg/m2, HD-Ara-C 4 × 2000 mg/m2, Amsacrine 4 × 100 mg/m2. RIC-regimen after 3 days of rest (d-3 to d-5): Fludarabine 3 × 30 mg/m2, Treosulfan 3 × 14 g/m2 (d-5 to d-3), ATG 10 mg/kg for MRD or 20 mg/kg for MUD, MMRD, MMUD from d -4 to d -2, pDLTs at day + 120 or 30 days after discontinuation of immunosuppression, 1–5 × 106 CD3+ cells/kg	20 (7.5%)
FM (Fludarabine, Melphalan) Fludarabine 5 × 30 mg/m2 (d-8 to d-4), Melphalan 140 mg/m2 (d-4)	18 (6.8%)
Fludarabine, Treosulfan Fludarabine 5 × 30 mg/m2 on five consecutive days (d-6 to d-2), Treosulfan 3 × 10 g/m2 on three consecutive days (d-4 to d-2)	15 (5.6%)
FLAMSA-RIC Busulfan, Cyclophosphamide FLAMSA regimen (d-12 to d-9): Fludarabine 4 × 30 mg/m2, HD-Ara-C 4 × 2000 mg/m2, Amsacrine 4 × 100 mg/m2. RIC-regimen: Busulfan 4 × 0.8 mg/kg on four consecutive days (d-6 to d-4), Cyclophosphamide (2 × 60 mg/kg for MUD, MMRD and MMUD or 2 × 40 mg/kg for MRD, d-3 to d-2), ATG 10 mg/kg for MRD or 20 mg/kg for MUD, MMRD, MMUD from d-4 to d-2, pDLTs at day + 120 or 30 days after discontinuation of immunosuppression, 1–5 × 106 CD3+ cells/kg	8 (3.0%)
Other	30 (11.3%)

RIC reduced intensity conditioning, MRD matched related donor, MUD matched unrelated donor, MMRD mismatched related donor, MMUD mismatched unrelated donor, pDLTs prophylactic donor lymphocyte infusions, ATG antithymocyte globulin